Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bruno Mazza

Gastroenterology Elmira, NY Medical Doctor

NPI 1356450381 CMS profile 151753

555 Saint Josephs Blvd Ste M2, Elmira, NY 14901

Open in the dashboard

General payments

$19,520

1,134 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bruno Mazza of Elmira, NY is reported in the CMS Open Payments database as having received $19,520 across 1,134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,982 208
2024 General $3,047 182
2023 General $3,070 206
2022 General $2,659 140
2021 General $2,798 150
2020 General $1,848 107
2019 General $2,117 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruno Mazza
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Bruno Mazza were reported at $3,982. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Bruno Mazza Gastroenterology median Middle half National median
2019 $2,117 $417 $126–$1,100 $163
2020 $1,848 $224 $74–$624 $114
2021 $2,798 $352 $106–$1,054 $132
2022 $2,659 $448 $129–$1,270 $149
2023 $3,070 $533 $150–$1,390 $160
2024 $3,047 $605 $160–$1,606 $164
2025 $3,982 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $4,065 221 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,917 228 payments
  3. Janssen Biotech, Inc. $2,795 233 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $2,390 116 payments
  5. Regeneron Healthcare Solutions, Inc. $1,020 29 payments
  6. Ardelyx, Inc. $627 24 payments
  7. Madrigal Pharmaceuticals $580 20 payments
  8. Pfizer Inc. $558 49 payments
  9. Celgene Corporation $502 37 payments
  10. Intercept Pharmaceuticals, Inc. $452 22 payments
  11. Other $3,614 155 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,868 1,126 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $308 2 payments
  3. Education $294 5 payments
  4. Consulting Fee $50 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $2,686 215 payments
  2. STELARA $2,324 164 payments
  3. ENTYVIO $1,830 82 payments
  4. LINZESS $1,088 64 payments
  5. PLENVU $1,028 80 payments
  6. RINVOQ $917 49 payments
  7. CREON $910 50 payments
  8. TREMFYA $871 73 payments
  9. HUMIRA $846 48 payments
  10. SKYRIZI $755 48 payments
  11. Other $8,765 448 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

2,043

Median for Gastroenterology: 569

Drug cost

$2,303,772

Median for Gastroenterology: $104,976

Branded share of claims

41.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 45 $1,119,362
Xifaxan Rifaximin Brand 80 $255,106
Humira(Cf) Pen Adalimumab Brand 23 $161,200
Motegrity Prucalopride Succinate Brand 163 $140,359
Dupixent Pen Dupilumab Brand 17 $119,061
Creon Lipase/Protease/Amylase Brand 27 $100,362
Linzess Linaclotide Brand 70 $57,043
Mesalamine Generic 83 $49,743
Zenpep Lipase/Protease/Amylase Brand 11 $47,387
Mesalamine Dr Mesalamine Brand 35 $42,831

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$68,087

Medicare's payments for the services billed

Medicare patients

449

Average age 73

Services billed

1,034

240 women, 209 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 35%
Ischemic heart disease 27%
Depression 21%
Chronic kidney disease 18%
Cancer 18%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
$365 45 —
XIFAXAN
$354 80 —
DUPIXENT
$289 17 —
SKYRIZI
$233 — —
ENTYVIO
$192 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

1,134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record